Example ImageÃÀ¸ß÷

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ £¬£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
News information
ÐÂÎÅ×ÊѶ

ÃÀ¸ß÷ҩЧЧÀ͸³ÄÜFirst-in-Class·ºËØ»¯ÒÖÖÆ¼ÁÑз¢

2022-11-24
|
»á¼ûÁ¿£º

·ºËØ-ÂѰ×øϵһÇУ¨UPS£©¹¦Ð§ÔÓÂÒÓë¶àÖÖ¼²²¡µÄ±¬·¢¾ßÓÐÇ×½ü¹ØÏµ £¬£¬£¬£¬°üÀ¨Ö×Áö¡¢ÐÄѪ¹Ü¼²²¡¡¢Éñ¾­ÍËÐÐÐÔ¼²²¡µÈ¡£¡£¡£¡£Òò´Ë £¬£¬£¬£¬UPSÒѾ­³ÉΪÏà¹Ø¼²²¡ÖÎÁƵÄÈÈÃŰеãÖ®Ò»¡£¡£¡£¡£ÒÖÖÆ·ºËØ-ÂѰ×øϵһÇÐ £¬£¬£¬£¬µ÷¿ØÏà¹Øµ×ÎïÂѰ׵Ľµ½â £¬£¬£¬£¬ÊµÏÖ¼²²¡ÖÎÁÆÊÇÖ÷ÒªµÄÒ©Î↑·¢²ßÂÔ £¬£¬£¬£¬ÏÖÔÚ°ÐÏò·ºËØ-ÂѰ×øϵһÇеÄС·Ö×ÓÒÖÖÆ¼ÁÑо¿Ö÷ÒªÓзºËػøE1ÒÖÖÆ¼Á¡¢·ºËØÁ¬ÏµÃ¸E2ÒÖÖÆ¼Á¡¢·ºËØÅþÁ¬Ã¸E3ÒÖÖÆ¼ÁÒÔ¼°ÂѰ×øÌåÒÖÖÆ¼ÁµÈ¡£¡£¡£¡£

TAK-243ÊÇÒ»ÖÖÊ×´´µÄ£¨First-in-Class£©¡¢¸ßЧµÄ·ºËػøE1 (UAE) ÒÖÖÆ¼Á¡£¡£¡£¡£Ñо¿·¢Ã÷TAK-243¾ßÓÐÏÔÖøµÄ¿¹Ö×Áö»îÐÔ¡£¡£¡£¡£ÆäÖÐ £¬£¬£¬£¬¿ÆÑÐְԱͨ¹ýÃÀ¸ß÷ʹÓÃHCC-70Ä£×Ó¾ÙÐÐÌåÄÚҩЧʵÑé¡£¡£¡£¡£Ð§¹û·¢Ã÷Ö×ÁöÉú³¤ÒÖÖÆÂÊ(TGI)µÖ´ï91%¡£¡£¡£¡£±¾ÆªÎÄÕÂÁ¬ÏµÎÄÏ×±¨µÀºÍÃÀ¸ß÷ҩЧ²¿·ÖµÄÂÄÀú £¬£¬£¬£¬·ÖÏí·ºËØ»¯ÒÖÖÆ¼ÁÑз¢µÄҩЧÑо¿°¸Àý £¬£¬£¬£¬Ï£Íû¶Ô¹Ø×¢·ºËØ»¯Ñо¿ºÍÖ×ÁöҩЧµÄÁÐλ¿ÆÑÐÊÂÇéÕßÓÐËù×ÊÖú¡£¡£¡£¡£

·ºËØ»¯

·ºËØ·Ö×ÓÔÚһϵÁÐÌØÊâµÄø×÷ÓÃÏ £¬£¬£¬£¬½«Ï¸°ûÄÚµÄÂѰ×ÖÊÆÊÎö £¬£¬£¬£¬´ÓÖÐÑ¡³ö°ÐÂѰ׷Ö×Ó £¬£¬£¬£¬²¢¶Ô°ÐÂѰ׾ÙÐÐÌØÒìÐÔÐÞÊεÄÀú³Ì¡£¡£¡£¡£·ºËØ»¯ÔÚÂѰ×ÖʵĶ¨Î»¡¢´úл¡¢¹¦Ð§µ÷ÀíºÍ½µ½âÖж¼Æð×ÅÊ®·ÖÖ÷ÒªµÄ×÷Óà £¬£¬£¬£¬Ò²¼ÓÈëÁËϸ°ûÖÜÆÚ¡¢Ï¸°ûÔöÖ³¡¢Ï¸°ûµòÍö¡¢Ï¸°û·Ö½â¡¢×ªÒÆ¡¢»ùÒò±í´ï¡¢×ªÂ¼µ÷Àí¡¢ÐźŴ«µ¼¡¢ËðÉËÐÞ¸´¡¢ÃâÒßÑ×Ö¢µÈÖÚ¶àÉúÔËÆø¶¯µÄµ÷¿Ø¡£¡£¡£¡£

·ºËØ-ÂѰ×øϵһÇÐ

·ºËØ-ÂѰ×øϵһÇÐ (Ubiquitin-Proteasome System £¬£¬£¬£¬UPS) ÊÇϸ°ûÄÚÈÏÕæÂѰ×Öʽµ½âµÄ¶à×é·Öϵͳ £¬£¬£¬£¬½éµ¼ÕæºËÉúÎï80%ÒÔÉϵÄÂѰ×Öʽµ½â £¬£¬£¬£¬¼ÓÈëϸ°ûµÄÉú³¤¼°·Ö½â¡¢DNA¸´ÖÆÓëÐÞ¸´¡¢Ï¸°û´úл¡¢ÃâÒß·´Ó¦µÈ¡£¡£¡£¡£·ºËØ-ÂѰ×øϵһÇУ¨ubiquitin-proteasome system £¬£¬£¬£¬UPS£©Ö÷ÒªÓÉ·ºËØ£¨ubiquitin £¬£¬£¬£¬Ub£©¡¢·ºËػøE1¡¢·ºËØÁ¬ÏµÃ¸E2¡¢·ºËØÅþÁ¬Ã¸E3¡¢È¥·ºËØ»¯Ã¸£¨deubiquitylating enzymes £¬£¬£¬£¬DUBs£©ºÍ26SÂѰ×øÌå×é³É¡£¡£¡£¡£

·ºËØ-ÂѰ×øϵһÇУ¨UPS).jpg

·ºËØ-ÂѰ×øϵһÇУ¨UPS)[1]

·ºËØ£¨ubiquitin £¬£¬£¬£¬Ub£©

·ºËØÊÇÒ»ÖÖÆÕ±éÂþÑÜÔÚÕæºËϸ°ûÖеĸ߶ÈÊØ¾ÉµÄС·Ö×ÓÂѰס£¡£¡£¡£µ¥¸ö·ºËØ·Ö×ÓÓÉ76¸ö°±»ùËá²Ð»ù×é³É¡£¡£¡£¡£Ö÷Òª¹¦Ð§ÊDZê¼ÇÐèÒªÆÊÎöµôµÄ°ÐÂÑ°× £¬£¬£¬£¬Ê¹Æä±»26SÂѰ×øÌå½µ½â¡£¡£¡£¡£·ºËØ»¹¿ÉÒÔ±ê¼Ç¿çĤÂÑ°× £¬£¬£¬£¬¼ÓÈëÂѰ×ÖʵĿçĤÔËÊä¡£¡£¡£¡£

·ºËؽṹͼ£¨ÈªÔ´£ºWikipedia£©.jpg

·ºËؽṹͼ£¨ÈªÔ´£ºWikipedia£©

·ºËػø£¨E1£©

·ºËػø,Ò²³ÆÎªE1ø £¬£¬£¬£¬ÊÇ·ºËØÓëµ×ÎïÂѰ×Á¬ÏµËùÐèÒªµÄµÚÒ»¸öø £¬£¬£¬£¬ÔڽṹÉϺ¬ÓÐλÖÃÀο¿µÄÊØ¾ÉµÄ°ëë×°±Ëá²Ð»ù £¬£¬£¬£¬Í¨¹ý°ëë×°±Ëá²Ð»ùÓë·ºËØµÄC¶ËÐγɸßÄÜÁòõ¥¼ü¶ø¼¤»î·ºËØ¡£¡£¡£¡£¹ØÓÚµ÷Àí·ºËØÎÈ̬ºÍÏÂÓηºËØ»¯ÒÀÀµÐÔϸ°ûÀú³Ì£¨°üÀ¨Í¨¹ý·ºËØ-ÂѰ×øϵһÇеÄÂѰ×Ë®½âºÍÑ¡ÔñÐÔ×ÔÊÉ£©¾ßÓÐÖ÷Òª×÷Óᣡ£¡£¡£

·ºËØÁ¬ÏµÃ¸£¨E2£©

ÔÚ·ºËØ»¯Àú³ÌÖÐ £¬£¬£¬£¬·ºËØÁ¬ÏµÃ¸E2ʩչºÜÊÇÖ÷ÒªµÄ×÷Óà £¬£¬£¬£¬ÊÇÆäÖбز»¿ÉÉÙµÄÖÐÐÄ»·½Ú¡£¡£¡£¡£·ºËØÁ¬ÏµÃ¸E2ÊÇÓÉÐí¶àÂѰ×ÖÊËù×é³ÉµÄ³¬¼Ò×å £¬£¬£¬£¬½á¹¹ºÍ¹¦Ð§·½Ãæ¶¼±£´æ¶àÑùÐÔ¡£¡£¡£¡£ËùÓеķºËØÁ¬ÏµÃ¸¶¼º¬ÓÐÒ»¸öÊØ¾É½á¹¹Óò¡ª¡ªUBC½á¹¹Óò¡£¡£¡£¡£·ºËØÁ¬ÏµÃ¸ (E2) ½«·ºËØ´Ó·ºËػø (E1) תÔ˵½·ºËØÅþÁ¬Ã¸ (E3) ºÍµ×ÎïÖÐÆðÒªº¦×÷Óᣡ£¡£¡£

·ºËØÅþÁ¬Ã¸£¨E3£©

·ºËØ»¯¼¶Áª·´Ó¦ÖеĵÚÈý¸öø £¬£¬£¬£¬´ß»¯½«Á¬ÏµÔÚ·ºËØÁ¬ÏµÃ¹ØÁ¬Ä·ºËØ×ª´ï¸øÄ¿µÄÂѰ×ÖÊ £¬£¬£¬£¬·ºËØÅþÁ¬Ã¸E3¾öÒé°ÐÂѰ׵ÄÌØÒìÐÔʶ±ð £¬£¬£¬£¬ÔÚ·ºËØ»¯Í¾¾¶ÖоßÓÐÖ÷Òª×÷Óᣡ£¡£¡£·ºËØÅþÁ¬Ã¸E3ͨ¹ýµ÷¿Øµ÷ÀíÂѰ׵ķºËØ»¯Àú³Ì¼ÓÈëϸ°ûÄڵĶàÖÖÐÄÀíÀú³Ì¡£¡£¡£¡£ËùÓеÄE3¶¼¾ßÓÐÅþÁ¬°ÐÂѰ׺ÍÌØ¶¨E2µÄÄÜÁ¦¡£¡£¡£¡£·ºËØÅþÁ¬Ã¸E3½á¹¹ÓòÖ÷Òª°üÀ¨HECT½á¹¹Óò¡¢RING½á¹¹ÓòºÍU-box½á¹¹Óò¡£¡£¡£¡£ÕýÊÇÓÉÓÚÕâÐ©ÖØ´ó¶à±äµÄE3¼Ò×å³ÉÔ±¿ÉÒÔ¶Ô²î±ðµ×Îï¾ÙÐÐÌØÒìÐÔʶ±ð £¬£¬£¬£¬·ºËØ»¯Í¾¾¶²Å·ºÆð³öÂѰ׽µ½âµÄ¸ß¶ÈÑ¡ÔñÐÔ¡£¡£¡£¡£

È¥·ºËØ»¯Ã¸£¨DUBs£©

È¥·ºËØ»¯Ã¸¼Ò×åÈÏÕæÍ¨¹ýË®½â·ºËØôÈ»ù×îºóµÄõ¥¼ü¡¢ëļü»òÒìëļü £¬£¬£¬£¬½«·ºËØ·Ö×ÓÌØÒìÐԵĴÓÁ´½ÓÓзºËصÄÂѰ×ÖÊ»òÕßǰÌåÂѰ×Ë®½âÏÂÀ´ £¬£¬£¬£¬Æðµ½È¥·ºËØ»¯µÄ×÷Óà £¬£¬£¬£¬¶ÔÂѰ׽µ½â¾ÙÐз´Ïòµ÷Àí £¬£¬£¬£¬´Ó¶øÓ°ÏìÂѰ×ÖʵĹ¦Ð§¡£¡£¡£¡£

ÂѰ×øÌå £¨Proteasome£©

26SÂѰ×øÌåÊǽµ½â·ºËØ»¯µ×ÎïµÄATPÒÀÀµÐÍÂѰ×Ë®½â¸´ºÏÌå £¬£¬£¬£¬ÓÉ20S½¹µã¿ÅÁ£¡¢19Sµ÷Àí¿ÅÁ£ºÍ11Sµ÷ÀíÒò×Ó×é³É¡£¡£¡£¡£26SÂѰ×øÌåÊÇ·ºËؽ鵼µÄÂѰ×Öʽµ½âµÄÖÐÐÄÂѰ×ø¡£¡£¡£¡£Í¨¹ý¿ØÖƼÓÈëϸ°ûµòÍö¡¢Ï¸°ûÖÜÆÚºÍÐźÅתµ¼µÄÒªº¦ÂѰ׵Ľµ½â £¬£¬£¬£¬ÔÚϸ°ûÎÈ̬ÖÐʩչÖ÷Òª×÷Óᣡ£¡£¡£ ÂѰ×øÌå¾ßÓжàÖÖ¹¦Ð§ £¬£¬£¬£¬ÊÇÒ©Î↑·¢µÄÖ÷Òª°Ð±ê £¬£¬£¬£¬ÌØÊâÊÇÔÚÖ×ÁöºÍÉñ¾­ÍËÐÐÐÔ¼²²¡ÖС£¡£¡£¡£ÔÚÒÑÍùµÄ¶þÊ®ÄêÖÐÒѾ­ÅжÏÁËÐí¶àÑ¡ÔñÐÔÂѰ×øÌåÒÖÖÆ¼Á²¢Åú×¼ÓÃÓÚÁÙ´²£¨È磺Bortezomib £¬£¬£¬£¬CarfilzomibµÈ£©¡£¡£¡£¡£

26SÂѰ×øÌå½á¹¹£¨ÈªÔ´£ºWikipedia£©.jpg

26SÂѰ×øÌå½á¹¹£¨ÈªÔ´£ºWikipedia£©

·ºËØ»¯Àú³Ì

? ÔÚATP¹©Ó¦ÄÜÁ¿µÄÇéÐÎÏ £¬£¬£¬£¬·ºËػøE1½«·ºËØ·Ö×ӻ £»£»£»£»ÐγÉE1-·ºËصÄÖÐÐIJúÆ· £»£»£»£»

? ·ºËػøE1½«»î»¯µÄ·ºËØ·Ö×Óת´ï¸ø·ºËØÁ¬ÏµÃ¸E2 £»£»£»£»ÐγÉÒ»¸öE2-·ºËصÄÖÐÐIJúÆ· £»£»£»£»

? ·ºËØÅþÁ¬Ã¸E3ÏÈʶ±ð´ý½µ½âµÄ°ÐÂÑ°× £¬£¬£¬£¬ÔÙ½«Á¬ÏµE2µÄ·ºËØÅþÁ¬µ½°ÐÂѰ×ÉÏ £¬£¬£¬£¬ÐγÉÒ»¸ö°üÀ¨E2-·ºËØÖÐÐIJúÆ·¡¢E3 øºÍ°ÐÂѰ׵ĸ´ºÏÎï £»£»£»£»

? E2 øºÍE3 ø £¬£¬£¬£¬´ÓÉÏÊöµÄ¸´ºÏÎïÖÐÊÍ·Å £¬£¬£¬£¬´Ó¶øÐγɱ»·ºËرê¼ÇµÄ°ÐÂÑ°× £»£»£»£»

? ÖØ¸´ÉÏÊöÀú³Ì £¬£¬£¬£¬Ö±µ½ÂѰ×ÖÊÉÏÅþÁ¬µÄ¶à¸ö·ºËØÐγÉÒ»Ìõ·ºËØÁ´ £»£»£»£»

? ±»·ºËØ»¯µÄ°ÐÂÑ°× £¬£¬£¬£¬±»26S ÂѰ×øÌåʶ±ðºÍ½µ½â¡£¡£¡£¡£

·ºËØ-ÂѰ×øÌå;¾¶.jpg

·ºËØ-ÂѰ×øÌå;¾¶[2]

·ºËػøE1ÒÖÖÆ¼Á

²¸È鶯ÎïÖеķºËØÅ¼ÁªÓÉÁ½ÖÖÒªº¦Ã¸Æô¶¯ £¬£¬£¬£¬¼´·ºËػøUAEºÍUBA6 £¬£¬£¬£¬ËüÃÇͳ³ÆÎªE1ø¡£¡£¡£¡£UAE£¨ÓÉUBA1»ùÒò±àÂ룩ÈÏÕæ99%ÒÔÉϵÄϸ°ûÄÚÂѰ׷ºËØ»¯ £¬£¬£¬£¬¶øUBA6ÈÏÕæ<1%µÄ·ºËØ»¯¡£¡£¡£¡£¾­µäµÄE1ø¾ù¾ßÓÐÏÙÜÕ»¯½á¹¹Óò(AD)¡¢´ß»¯°ëë×°±Ëá½á¹¹Óò(CCD)ÒÔ¼°·ºËØÕÛµþ½á¹¹Óò(UFD)¡£¡£¡£¡£Ê×ÏÈ £¬£¬£¬£¬ÔÚATPºÍMg2+±£´æÏ £¬£¬£¬£¬E1ø´ß»¯UbÓëATPÐγÉUb-AMP¼ÓºÏÎï²¢Á¬Ïµµ½E1øµÄAD½á¹¹Óò £¬£¬£¬£¬Í¬Ê±ÊÍ·ÅÊÇÁ×Ëá»ùÍÅPPi £¬£¬£¬£¬CCD½á¹¹ÓòµÄ°ëë×°±ËáÛÏ»ùÇ׺˽ø¹¥Ub-AMP¼üÐγÉUb-E1Áòõ¥¼ü²¢ÊÍ·ÅAMP £¬£¬£¬£¬ÁíÒ»¸öUb·Ç¹²¼ÛÁ¬Ïµµ½AAD½á¹¹Óò £¬£¬£¬£¬ÐγÉЯ´øÁ½¸öUb·Ö×ÓµÄE1ø¡£¡£¡£¡£È»ºó £¬£¬£¬£¬Ð¯´øÁ½·Ö×ÓUbµÄE1øÁ¬ÏµE2ø £¬£¬£¬£¬Í¨¹ýUFD½«Ub×ªÒÆµ½E2øÉÏ £¬£¬£¬£¬ÐγÉUb-E2¸´ºÏÎï £¬£¬£¬£¬½Ó׿ÓÈëÏÂÒ»¸öUbµÄ»î»¯¡£¡£¡£¡£Òò´Ë £¬£¬£¬£¬ÒÖÖÆE1ø»îÐÔÄܹ»×è¶Ï·ºËØ·Ö×ӵĻ £¬£¬£¬£¬ÒÖÖÆ·ºËØ»¯Àú³Ì £¬£¬£¬£¬ÊÇDZÔڵĿ¹Ö×Áö°Ðµã¡£¡£¡£¡£

First-in-Class UBA1ÒÖÖÆ¼ÁTAK-243

TAK-243£¨MLN7243£©ÊÇÓÉMillenniumÑз¢µÄµÚÒ»¸ö½øÈëÁÙ´²µÄUBA1ÒÖÖÆ¼Á £¬£¬£¬£¬´ÓÁè¼Ý700¸ö»¯ºÏÎïÖÐɸѡ·¢Ã÷µÄ £¬£¬£¬£¬Äܹ»ÓëUbÐγÉUb-TAK-243¼ÓºÏÎï £¬£¬£¬£¬½ø¶øÁ¬Ïµµ½UBA1µÄATPÁ¬ÏµÎ»µãÉÏ £¬£¬£¬£¬ÒÖÖÆUBA1»îÐÔ¡£¡£¡£¡£ÔÚ¶àÖÖ°©Ï¸°ûÖÐÄܹ»ÓÕµ¼·ºËؽ鵼µÄp53¡¢c-Jun¡¢c-Myc¡¢XIAPµÈÂѰ׻ýÀÛ²¢ÌåÏÖ³öÏÔ×ŵĿ¹Ö×Áö»îÐÔ £¬£¬£¬£¬ÏÖÔÚ´¦ÓÚÖÎÁÆÍíÆÚ¶ñÐÔʵÌåÁöµÄÒ»ÆÚÁÙ´²¡£¡£¡£¡£
TAK-243ÊÇÒ»ÖÖÊ×´´µÄ·ºËػø (UAE) ÒÖÖÆ¼Á¡£¡£¡£¡£Í¨¹ýÐγÉTAK-243-·ºËؼӺÏÎïÓÐÓÃÒÖÖÆUAE¡£¡£¡£¡£ÓÃTAK-243ÔÚÌåÍâ´¦Öóͷ£Ï¸°ûµ¼ÖÂϸ°û·ºËØÅ¼ÁªÎïɥʧ £¬£¬£¬£¬µ¼Ö·ºËØÒÀÀµÐÔÂѰ×ÖÊת»»ºÍÐźŴ«µ¼È±ÏÝ £¬£¬£¬£¬Ï¸°ûÖÜÆÚÀú³ÌÊÜËðºÍDNAÐÞ¸´È±ÏÝ £¬£¬£¬£¬ÂѰ׶¾ÐÔÓ¦¼¤ÔöÌí £¬£¬£¬£¬×îÖÕµ¼Ö°©Ï¸°ûéæÃü¡£¡£¡£¡£TAK-243ÔÚÌåÄÚÖÎÁÆÖ×Áöϸ°ûµ¼ÖÂϸ°û¶à·ºËØ»¯¼±¾çïÔÌ­ £¬£¬£¬£¬²¢ÔÚЯ´øÈËÒìÖÖÒÆÖ²Ö×ÁöµÄСÊóÖÐÓÕµ¼ÏÔÖøµÄ¿¹Ö×Áö»îÐÔ¡£¡£¡£¡£
TAK-243¾ßÓиßÑ¡ÔñÐÔ £¬£¬£¬£¬ÒÖÖÆUAE, UBA6, NAEºÍSAEµÄIC50Öµ»®·ÖΪ 1, 7 £¬£¬£¬£¬28 £¬£¬£¬£¬850  nM¡£¡£¡£¡£TAK-243-·ºËؼӺÏÎïÒ»µ©ÐÎ³É £¬£¬£¬£¬¾Í»áÓëUAEϸÃÜÁ¬Ïµ²¢×è¶ÏUAEµÄ´ß»¯»îÐÔ¡£¡£¡£¡£TAK-243ÒÖÖÆUAE½«·ºËØ·Ö×Ó×ªÒÆµ½E2ø¡£¡£¡£¡£

A-TAK-243-µÄ»¯Ñ§½á¹¹--B-TAK-243-·ºËؼӺÏÎïµÄ½á¹¹.jpg

A: TAK-243 µÄ»¯Ñ§½á¹¹  B: TAK-243-·ºËؼӺÏÎïµÄ½á¹¹[3]

TAK-243ÌåÄÚ¿¹Ö×Áö»îÐÔÑо¿

TAK-243µÄ¿¹Ö×Áö»îÐÔ»®·Öͨ¹ýʹÓÃPDX ºÍ CDXÖ×ÁöÄ£×Ó¾ÙÐÐÑо¿ÑéÖ¤µÄ¡£¡£¡£¡£8ÖÁ 12 ÖÜÁäСÊóµÄ²à¸¹Æ¤Ï½ÓÖÖÖ×ÁöË鯬»òÎÞѪÇå×÷Óý»ùÖеÄÖ×Áöϸ°ûÐüÒº¡£¡£¡£¡ £¿£¿£¿£¿£¿£¿ÆÑÐְԱʹÓà CDX Ä£×ÓÔÚСÊóÖн¨ÉèÁËÆ¤ÏÂÖ×Áö£ºWSU-DLCL2 (ÃÖÂþÐÔ´óBϸ°ûÁܰÍÁö)¡¢HCT-116£¨½á³¦°©£©¡¢THP-1£¨¼±ÐÔËèÐÔ°×Ѫ²¡£¡£¡£¡£©¡¢CWR22£¨Ç°ÏßÏÙ°©£©¡¢Calu-6 £¨·ÇСϸ°û·ÎÏÙ°©£©¡¢HCC-70£¨ÈýÒõÐÔÈéÏÙ°©£©ºÍ MM1.S£¨¶à·¢ÐÔ¹ÇËèÁö£© £¬£¬£¬£¬ÒÔ¼°PDX Ä£×Ó£ºPHTX-24c£¨½á³¦°©£©¡¢PHTX -132Lu£¨Ô­·¢ÐÔNSCLC£©¡¢PHTX-55B£¨ÈýÒõÐÔÈéÏÙ°©£©¡¢PHTX-235O£¨Âѳ²°©£©ºÍ HNM626£¨¹¬¾±°©£©¡£¡£¡£¡£
ÔÚ´ËÏîÑо¿ÖÐ £¬£¬£¬£¬¿ÆÑÐְԱͨ¹ýÃÀ¸ß÷ʹÓÃHCC-70Ä£×Ó¾ÙÐÐʵÑé¡£¡£¡£¡£ÔÚÿֻ´ÆÐÔÂãÊóµÄ¸¹²¿ÒÆÖ²5.0¡Á106 ¸öHCC-70ϸ°ûÐγÉHCC-70Ä£×Ó¡£¡£¡£¡£µ±Æ½¾ùÖ×ÁöÌå»ýµÖ´ïÔ¼ 200 mm3ʱ £¬£¬£¬£¬½«¶¯ÎïËæ»ú·Ö×é £¬£¬£¬£¬Ã¿×é 8Ö»¶¯Îï¡£¡£¡£¡£ÔÚËæºóµÄ21Ììʱ¼äÄÚ°´Ã¿ÖÜÁ½´Î¸øÒ©TAK-243£¨12.5mg/kg) ºÍ±ÈÕÕ×é (20% HP¦ÂCD)¡£¡£¡£¡£Ã¿Öܼà²âÁ½´ÎÖ×ÁöÉú³¤ºÍ¶¯ÎïÌåÖØ¡£¡£¡£¡£×îºóÒ»´Î¸øÒ©ºó5ÌìÄÚÅÌËãTGI¡£¡£¡£¡£

TAK-243¶ÔHCC-70µÄÉú³¤ÒÖÖÆÇúÏß.jpg

TAK-243¶ÔHCC-70µÄÉú³¤ÒÖÖÆÇúÏß[3]

Ñо¿·¢Ã÷ TAK-243 ÔÚËùÓмì²éµÄÄ£×ÓÖж¼ÓÕµ¼ÁËÏÔÖøµÄ¿¹Ö×Áö»îÐÔ·´Ó¦¡£¡£¡£¡£ÆäÖжÔCWR22¡¢PHTX-235O¡¢HCC-70ºÍPHTX-55BµÄTGIµÖ´ï90%ÒÔÉÏ¡£¡£¡£¡£Í¬Ê±¶Ô¶¯ÎïÌåÖØÏÕЩûÓÐÓ°Ïì¡£¡£¡£¡£

TAK-243ÌåÄÚ¿¹²î±ðÖ×ÁöµÄ»îÐÔ.jpg

TAK-243ÌåÄÚ¿¹²î±ðÖ×ÁöµÄ»îÐÔ[3]

×ܽáÓëÕ¹Íû

·ºËØÔÚµ÷Àíϸ°ûÂѰ×ÖÊÎÈ̬ºÍÐźŴ«µ¼ÖеIJî±ð×÷ÓÃÍ»³öÁ˰ÐÏò UPS µ÷ÀíÈËÀ༲²¡µÄ¿ÉÄÜÐÔ¡£¡£¡£¡£Ö»¹ÜÓÐÕâÖÖDZÁ¦ £¬£¬£¬£¬µ«ÔÚ UPS ÖÐÉæ¼°µÄ 500¶àÖÖøÖÐ £¬£¬£¬£¬Ö»ÓÐһС²¿·ÖÊÇÒѽøÈëÁÙ´²Ñо¿Ò©Îï¿É°ÐÏòµÄ¡£¡£¡£¡£ÂѰ×øÌåÒÖÖÆ¼ÁBortezomibµÄÁÙ´²ÀÖ³ÉÒýÆðÁËÈËÃÇ¶Ô UPS µÄÆäËûÒòËØ¾ÙÐÐÑо¿µÄÐËȤºÍÈÈÇé¡£¡£¡£¡£TAK-243ÊÇÒ»ÖÖÊ×´´µÄ¡¢¸ßЧµÄUAEÒÖÖÆ¼Á £¬£¬£¬£¬¿ÉÍêÈ«ÒÖÖÆÏ¸°û·ºËØ»¯ £¬£¬£¬£¬µ¼Ö·ºËØÒÀÀµÐÔÂѰ×Ë®½âÊÜËð¡¢ER Ó¦¼¤ÒÔ¼°Ï¸°ûÖÜÆÚÀú³ÌºÍ DNA ËðÉËÐÞ¸´ÊÜË𡣡£¡£¡£ÌåÄÚÍâÊý¾ÝÅú×¢ TAK-243 ͨ¹ýUAEÒÖÖÆÊ©Õ¹Æä×÷Óᣡ£¡£¡£TAK-243µÄ·¢Ã÷ΪÑо¿ÂѰ×ÖÊ·ºËØ»¯ÌṩÁËÒ»¸öÓмÛÖµµÄ¹¤¾ß £¬£¬£¬£¬²¢ÎªÑо¿ÂѰ×ÖÊÎÈ̬ºÍ·ºËØÐźŴ«µ¼ÒÔÓÃÓÚÖ×ÁöÑо¿ÌṩÁËеÄʱ»ú¡£¡£¡£¡£·ºËØ-ÂѰ×øϵһÇÐÊǶàÖÖ¼²²¡ÌØÊâÊÇÖ×ÁöµÄÖ÷Òª°Ðµã £¬£¬£¬£¬°ÐÏò¸Ãϵͳ»á»ñµÃ¸ü¸ßµÄÑ¡ÔñÐÔ¡£¡£¡£¡£

²Î¿¼ÎÄÏ×

[1] Marie W Wooten, et al.  Signaling, polyubiquitination, trafficking, and inclusions: sequestosome 1/p62's role in neurodegenerative disease. J Biomed Biotechnol. 2006;2006(3):62079.doi: 10.1155/JBB/2006/62079.

[2]Ashok N Hegde, et al. The ubiquitin-proteasome pathway in health and disease of the nervous system. Trends Neurosci. 2007 Nov;30(11):587-95. doi: 10.1016/j.tins.2007.08.005. Epub 2007 Oct 24.

[3]Marc L Hyer, et al. A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment. Nat Med. 2018 Feb;24(2):186-193. doi: 10.1038/nm.4474. Epub 2018 Jan 15.

[4] Isabella A Lambert-Smith, et al. The pivotal role of ubiquitin-activating enzyme E1 (UBA1) in neuronal health and neurodegeneration. Int J Biochem Cell Biol . 2020 Jun;123:105746. doi: 10.1016/j.biocel.2020.105746. Epub 2020 Apr 18.

[5] H. Yang, X. Chen, K. Li, et al. Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment. Seminars in Cancer Biology. 2021, 68:105-122.

[6] L. Cappadocia, C. D. Lima. Ubiquitin-like Protein Conjugation: Structures, Chemistry, and Mechanism. Chem Rev. 2018, 118(3): 889¨C918.

[7] J. A. Harrigan, X. Jacq, N. M. Martin, et al. Deubiquitylating enzymes and drug discovery: emerging opportunities. Nat Rev Drug Discov. 2018, 17(1): 57¨C78.

ÃÀ¸ß÷ҩÀíҩЧЧÀÍ

ÐÂÒ©Ñз¢µÄÍ»ÆÆÁ¢Òì £¬£¬£¬£¬Àë²»¿ªÖÖÖֿƼ¼Æ½Ì¨µÄǿʢ֧³Ö¡£¡£¡£¡£½üÄêÀ´ £¬£¬£¬£¬Ò©ÀíҩЧÆÀ¼Û¡¢¶¯ÎïÄ£×ӺͻùÒò&ϸ°ûÁÆ·¨µÈ¼¼ÊõÒ»Ö±µü´ú¸üР£¬£¬£¬£¬·ÉËÙÉú³¤ £¬£¬£¬£¬¶¯ÎïÄ£×ÓÒÑÔÚÐÂÒ©Ñз¢Àú³ÌÖÐʩչ×ÅÖ÷Òª×÷Óᣡ£¡£¡£²î±ð¼²²¡¶¯ÎïÄ£×ӵĽ¨ÉèΪÑо¿¼²²¡±¬·¢ÓëÉú³¤»úÖÆ¡¢É¸Ñ¡ºÍÆÀ¼Û¿¹¼²²¡Ò©ÎïÌṩÁËÓÐÁ¦µÄ¹¤¾ß¡£¡£¡£¡£ÃÀ¸ß÷ӵÓÐÔ¼30000ƽ·½Ã×ʵÑéÊÒ £¬£¬£¬£¬Í¨¹ýAAALACÈÏÖ¤ £¬£¬£¬£¬¼ÓÉϸ»×ãµÄ¶¯Î﹩Ӧ £¬£¬£¬£¬¿ÉÒÔÖ´ÐÐСÊó¡¢´óÊó¡¢Íá¢Öí¡¢¹·¡¢ºïµÈ¶¯ÎïµÄ¶¯ÎïÄ£×Ó¹¹½¨¡£¡£¡£¡£
ÃÀ¸ß÷ҩÀíҩЧ²¿½ô¸úÐÐÒµÉú³¤ÓëÊг¡ÐèÇó £¬£¬£¬£¬Ò»Ö±ÍêÉÆÁ¢Òì £¬£¬£¬£¬¾­ÓɶàÄêµÄÂÄÀúÀÛ»ý £¬£¬£¬£¬¶à·½ÑéÖ¤ºÍºã¾Ãʵ¼ùÄ¥Á· £¬£¬£¬£¬½¨ÉèÁËÍêÉÆµÄ¶¯ÎïÄ£×Ó¿â £¬£¬£¬£¬¿Éƾ֤¿Í»§µÄÐèÇóÌṩÖÖÖÖÓÐÓõ͝ÎïÄ£×Ó £¬£¬£¬£¬ÓÃÀ´¼ì²âÒ©ÎïµÄÓÐÓÃÐÔ¡£¡£¡£¡£ÊµÑ鶯ÎïÓзÇÈËÁ鳤ÀදÎȮ¡¢¾ÞϸÊó¡¢Íá¢ëàÊó¡¢Ð¡ÐÍÖíµÈÖÖÀà¡£¡£¡£¡£

?  Òѽ¨Éè¿ìÒª300ÖÖÖ×ÁöÆÀ¼ÛÄ£×Ó £¬£¬£¬£¬Í¬Ê±ÎÒÃÇΪÁ¢ÒìÁÆ·¨¸³ÄÜ £¬£¬£¬£¬ÖÜÈ«½á¹¹Ö×ÁöÃâÒßÁÆ·¨µÄÆÀ¼ÛºÍÑо¿ £¬£¬£¬£¬ÒÑÍê³ÉCAR-T £¬£¬£¬£¬TCR-T, CAR-NK, ÈÜÁö²¡¶¾, ¿¹Ì壨µ¥¿¹ £¬£¬£¬£¬Ë«¿¹ £¬£¬£¬£¬¶à¿¹µÈ£© £¬£¬£¬£¬siRNA, AAVµÈÃâÒßÁÆ·¨µÄÄ£×Ó½¨É輰ҩЧÆÀ¼Û¡£¡£¡£¡£

?  Æ¾Ö¤¿Í»§µÄÐèÇóÌṩÖÖÖÖÓÐÓõ͝ÎïÄ£×Ó£¨Éö˥ģ×Ó¡¢ÑªÐ鶯ÎïÄ£×Ó¡¢Î¸ËáÉøÍ¸¶¯ÎïÄ£×Ó¡¢Î¸À£ÑñÄ£×ӵȣ© £¬£¬£¬£¬ÓÃÀ´¼ì²âÒ©ÎïµÄÓÐÓÃÐÔ¡£¡£¡£¡£Í¨ÀýµÄÏû»¯ÏµÍ³¼²²¡ÓУºÎ¸ËáÉøÍ¸¡¢Î¸À£Ññ¡¢ÉöË¥µÈ £¬£¬£¬£¬Í¨¹ý´óÊó¾ÙÐж¯ÎïʵÑé¡£¡£¡£¡£

?  ÔÚ´úлÐÔ¼²²¡ÁìÓò¾ßÓÐÊýÊ®¸öÎȹÌÓÐÓõ͝ÎïÄ£×Ó £¬£¬£¬£¬ÓÈÆä¹ØÓÚÁÙ´²È±·¦ÓÐÓÃÒ©ÎïÖÎÁÆ¡¢ÇÒ½üÆÚÑÐÉúÆøÈȵÄNAFLD¼²²¡ÁìÓò¾ßÓи»ºñµÄÂÄÀúºÍÓÐÓõ͝ÎïÄ£×Ó¡£¡£¡£¡£

?  ÎªÑ×Ö¢ÃâÒß¼²²¡Ò©ÎïµÄҩЧÆÀ¼ÛÌṩÁ˶àÖÖÕë¶Ô²î±ð°Ðµã¼°Í¨Â· £¬£¬£¬£¬Îȹ̿ɿ¿ £¬£¬£¬£¬ÓµÓÐÓÅÒìÆÀ¼ÛÄÜÁ¦µÄ¶¯ÎïҩЧÆÀ¼ÛÄ£×Ó £¬£¬£¬£¬ÎªÐÂÒ©µÄÁÙ´²×ª»¯ÌṩÖúÁ¦¡£¡£¡£¡£

?  ½¨ÉèÁ˺­¸Ç¿¹ÒÖÓôÒ©¡¢¿¹ÍíÄê³Õ´ôÖ¢Ò©¡¢Õò¾²´ßÃß¿¹½¹ÂÇÒ©¡¢ÕòÍ´Ò©¡¢¿¹¾ªØÊÒ©¡¢¿¹ÅÁ½ðÉ­ÊÏÖ¢Ò©ÒÔ¼°¿¹¾«ÉñÆÆËéÖ¢Ò©µÈÖڶ༲²¡¾«Éñϵͳ¼²²¡Ä£×ÓÆÀ¼Û¼¼Êõ £¬£¬£¬£¬¿ÉÒÔ´Ó·Ö×Óˮƽ¡¢Ï¸°ûˮƽ¡¢Ex-vivo¡¢invivoµÈ¶à²ãÃæÖÜÈ«ÆÀ¼ÛÒ»ÀàÁ¢ÒìÒ©Îï¡£¡£¡£¡£

?  Æ¾Ö¤¿Í»§µÄÐèÇóÌṩÖÖÖÖÓÐÓõ͝ÎïÄ£×Ó £¬£¬£¬£¬Í¨ÀýµÄ¶¯ÎïÄ£×ÓÓУºÈ«²ãƤ·ô´´É˼²²¡¶¯ÎïÄ£×Ó¡¢Ñ¹´¯À£Ññ¼²²¡¶¯ÎïÄ£×Ó¡¢×Ô¾õÐÔ¸ßѪѹ´óÊó¼²²¡¶¯ÎïÄ£×ÓµÈ £¬£¬£¬£¬Í¨¹ý¾ÞϸÊó¡¢SHR´óÊóµÈ¾ÙÐж¯ÎïʵÑé¡£¡£¡£¡£

Ïà¹ØÐÂÎÅ
PROTACÔõÑùÕ÷ÓÃÈËÌå´úл»úÖÆÆðµ½Ò©Îï×÷Óà £¿£¿£¿£¿£¿£¿
2021-06-02
PROTAC¼¼ÊõµÄÎÊÊÀΪ½â¾öС·Ö×ÓÒ©ÎïÎÞ·¨×÷ÓõÄÂÑ°×°Ðµã´øÀ´Á˼«´óµÄDZÁ¦ £¬£¬£¬£¬2017ÄêÒÔºó £¬£¬£¬£¬PROTAC¼¼Êõ·ÉËÙÉú³¤ £¬£¬£¬£¬´ÓʵÑéÊÒ×ßÏò¹¤Òµ½ç £¬£¬£¬£¬Ò©ÎïÑз¢¾ÞÍ·¾ù·×·×¼ÓÈë¸ÃÐÐÁÐ £¬£¬£¬£¬°üÀ¨»ÔÈ𠣬£¬£¬£¬ÂÞÊÏ £¬£¬£¬£¬GSK £¬£¬£¬£¬Ä¬¿Ë £¬£¬£¬£¬Åµ»ª £¬£¬£¬£¬Ä¬É³¶«¡¢°¬²®Î¬¡¢¼ªÏéµÂ¡¢°ÙʱÃÀÊ©¹ó±¦µÈ......
¡¾ÔÆ¿ÎÌá¿PROTAC:½â·ÅÎÞ³ÉÒ©Ð԰еãµÄÏÈ·æ
2020-03-13
2020Äê3ÔÂ13ÈÕÏÂÖç £¬£¬£¬£¬ÃÀ¸ß÷¿ªÆôÁËÏßÉÏÖ±²¥¿Î³ÌµÚÈý½² £¬£¬£¬£¬ÓÉÃÀ¸ß÷»¯Ñ§²¿¸±×ܲÃÂíÐËȪ²©Ê¿×öרÌⱨ¸æ¡¶PROTAC£º½â·ÅÎÞ³ÉÒ©Ð԰еãµÄÏÈ·æ¡· £¬£¬£¬£¬»¶Ó­Ô¢Ä¿»Ø·ÅÊÓÆµ¡£¡£¡£¡£
LYTAC³öÉú £¬£¬£¬£¬ÓëPROTAC²¢¼ç×÷Õ½Õë¶Ô²»¿É³ÉÒ©µÄ°Ðµã
2020-08-28
7ÔÂ29ÈÕ £¬£¬£¬£¬×îнÒÏþÔÚNatureÔÓÖ¾ÉϵÄÒ»ÏîÑо¿ÖÐ £¬£¬£¬£¬À´×Ô˹̹¸£´óѧµÄ¿ÆÑ§¼ÒÍŶӱ¨µÀÁËÒ»ÖÖ²î±ðµÄÂѰ׽µ½â¼¼Êõ¡ª¡ªÈÜøÌå°ÐÏòǶºÏÌ壨lysosome-targeting chimaeras, LYTACs£© £¬£¬£¬£¬Îª°ÐÏò½µ½âϸ°ûÍâÒÔ¼°Ä¤Á¬ÏµÂѰ׿ª·¢ÁËеĿÉÄÜ¡£¡£¡£¡£
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿